AbbVie Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1 North Waukegan Road North Chicago IL United States 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets medicines and therapies across immunology, oncology, neuroscience, virology, and other disease areas, along with branded and generic pharmaceutical products and contract development and manufacturing services. The company provides a broad portfolio of prescription medicines, biologics, and consumer health products through pharmaceutical brands such as Humira (adalimumab), Imbruvica, Zyloprim, Creon, and Botox in related segments, complemented by a robust pipeline of investigational therapies and biosimilars. Main products and services: therapeutic biologics and small-molecule drugs for immunology, oncology, neuroscience, infectious diseases, and metabolic disorders; contract development and manufacturing services (CDMO) for biopharmaceuticals; research and development activities including clinical trial support, regulatory affairs expertise, and process development; commercialization and sales of prescription pharmaceuticals; portfolio management and lifecycle extension strategies; patient support programs; regulatory affairs and pharmacovigilance; manufacturing and quality control across global facilities; scientific advisory and medical information services; Kendall, AbbVie Medicine, Allergan Aesthetics, and other branded product lines through regional offices and distributors; biosimilars development and collaboration programs; over-the-counter and consumer health products in some markets; partnerships for drug discovery, development, and commercialization. Latest major company changes: expands collaboration agreements with biopharma partners focusing on innovative therapies; completes acquisitions and divestitures to optimize portfolio and geographic reach; launches new therapies and expands indications in oncology and immunology; announces strategic shifts toward higher-value biologics and rare diseases; undergoes organizational restructuring and potential rebranding moves to enhance commercial efficiency; scales manufacturing capacity and supply chain resilience in North America, Europe, and Asia; establishes or expands global partnerships for research, development, and commercialization in multiple markets. Additional context: operates across biopharmaceutical research, development, manufacturing, and commercialization; serves global healthcare providers, hospitals, clinics, and wholesale distributors; geographic footprint includes North America, Europe, Asia-Pacific, and emerging markets; founded in 1989 with headquarters in North Chicago, Illinois; has multiple subsidiaries and affiliates under AbbVie Inc. and strategic relationships with partners and contract manufacturers to support a wide therapeutic portfolio.
Company News
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
AbbVie Inc. $ABBV Stock Sold by Axxcess Wealth Management LLC
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
AbbVie Inc. $ABBV Position Boosted by Focused Alpha LLC
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Novem Group Sells 3,428 Shares of AbbVie Inc. $ABBV
Greg Jennings LLC Makes New Investment in AbbVie Inc. $ABBV
15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
AbbVie Inc. $ABBV Shares Sold by First Bank & Trust
1,939 AbbVie Inc. $ABBV Shares Acquired by IFP Advisors Inc
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
/C O R R E C T I O N - AbbVie/